Navigation Links
Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
Date:10/29/2008

SOUTH SAN FRANCISCO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3 at 3:20 p.m. EST at The Waldorf Astoria Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Rigel to Webcast Investor Update on October 27, 2008
2. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
3. Rigel to Present at Collins Stewart Growth Conference
4. Rigel Announces First Quarter 2008 Financial Results
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
8. Rigel Announces Offering of 4,000,000 Shares of Common Stock
9. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
10. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
11. Rigel Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... offer hope for future treatments targeting growth factor, researchers ... The spread of breast cancer cells from the main ... by a growth factor known as TGFb, which may ... metastatic breast cancer, British researchers say. , Previous studies ... normal cell growth and movement. In this new study, ...
(Date:12/6/2009)... Sickle cell disease, a condition characterized ... one of the most common genetic blood disorders ... more than 70,000 Americans.(1) Research presented today at ... of Hematology highlights intriguing studies on the acute ... with this blood disorder, evaluations of both new ...
(Date:12/6/2009)... Volunteer organizations and members of the community, in cooperation with the ... create a holiday party. This year,s attendance is expected to soar ... , ... (PRWEB) December 6, 2009 -- ... Greater VA Healthcare System in West Los Angeles, will once again ...
(Date:12/5/2009)... Dec. 5 ,, What: Cuts for ... difference in the fight against cancer and other terminal illnesses ... be donated to St. Jude Children,s Research Hospital. Guests will ... a delectable and savory Vietnamese restaurant in Falls Church for ...
(Date:12/5/2009)... triggers, experts advise , , SATURDAY, Dec. 5 (HealthDay News) ... asthma can have bad reactions to certain holiday traditions ... and wheezing, according to the American College of Allergy, ... to live evergreens may choose to decorate with artificial ...
Breaking Medicine News(10 mins):Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Keep Asthma, Allergies at Bay for the Holidays 2
... Jersey Senator Jennifer Beck (Republican, District 12) will serve as ... Marketing Association,s (HCMA) Annual Conference taking place at ... 2009.In accordance with the event,s theme -- Responding to ... -- Senator Beck will focus on how the economy ...
... Electric Chief Medical Officer Join Health Care Leaders to Address ... URAC , the leading health care accreditation and ... , author, advocate and mother of cycling champion ... of Health Services and Chief Medical Officer for ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... stimuli may also key personality disorders , , TUESDAY, May ... process pleasurable experiences such as sweet tastes and sexual ... individual is a "people person," say European researchers. ... 41 males who,d completed a questionnaire designed to measure ...
... angioplasty is done, the lower the death rate, study ... having a heart attack should be given balloon angioplasty ... their risk of dying, a new study concludes. , ... to open blocked coronary arteries. , For the study, ...
... Reflected in Burgeoning Pipeline of More than 400 Drugs ... ResourcesWALTHAM, Mass., May 20 Decision Resources, one of ... and healthcare issues, finds that the launch and uptake ... next 10 years will drive the type 2 diabetes ...
Other Medicine News:Health News:New Jersey Senator to Serve as Keynote Speaker for the HCMA Annual Conference 2Health News:Linda Armstrong Kelly and Dr. Robert Galvin Keynote URAC 10th Annual Quality Summit 2Health News:Linda Armstrong Kelly and Dr. Robert Galvin Keynote URAC 10th Annual Quality Summit 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Being a 'People Person' May Be All in Your Head 2Health News:With Heart Attacks, Fast Treatment Matters 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2
(Date:12/4/2009)... The U.S. Food and Drug Administration (FDA) today approved ... the treatment of schizophrenia and manic or mixed episodes ... years old. ,, The updated Zyprexa label states ... for weight gain and hyperlipidemia in adolescents compared to ...
(Date:12/4/2009)... Ensure Emergency Deliveries are Transported ,, PHILADELPHIA, ... chapter of the American Red Cross are hard at ... that they endure that could potentially put Philadelphia,s blood ... on strike and set up a picket line yesterday ...
(Date:12/4/2009)... Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... enrolled in the company,s Phase II-b, dose escalation, clinical ... traumatic brain injury (TBI). Oxycyte is the Company,s perfluorocarbon ... invaluable importance in improving the outcome of patients with ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Constipation May Lead to Other Problems 50223 1Constipation May Lead to Other Problems 50223 2Constipation May Lead to Other Problems 50223 3Jackson International Launches New Website in Collaboration with Medicaview International 50220 1Jackson International Launches New Website in Collaboration with Medicaview International 50220 2Jackson International Launches New Website in Collaboration with Medicaview International 50220 3Jackson International Launches New Website in Collaboration with Medicaview International 50220 4The science of hammering 9025 1
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: